Products
Platform
Research
Market
Learn
Partner
Support
IPO

V

Valiant Laboratories Share Price

64.71
-0.24 (-0.37%)
VALIANTLAB • 16 Jan, 2026 | 03:29 PM
The current prices are delayed, login or Open Demat Account for live prices.

Valiant Laboratories Stock Performance

1W Return-3.69
1Y Return-38.32
Today's Low63.75
Prev. Close64.95
Mkt Cap (Cr.)351.46
1M Return-0.80
3Y Return0.00
52-Week High115.54
Open67.30
PE Ratio51.29
6M Return-42.14
Today's High67.3
52-Week Low63.5
Face Value10

Valiant Laboratories Company background

Founded in: 2021
Managing director: Santosh S. Vora
Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s. Bharat Chemicals through deed of partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Company to Valiant Laboratories Limited via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually, commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or parahydroxyacetanilide C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the firstline therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. It manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of customers.Paracetamol is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Presently, the Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals. The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an inhouse RD infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in existing product. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL). In July, 2022 the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) to diversify the business activities.The Company launched a public issue comprising a fresh issue of 10,890,000 equity shares of Rs 10 each by raising funds of Rs 15.24 crore on October 03, 2023.Company enhanced the manufacturing capacity of the Tarapur plant from 750 MT to 900 MT per month in FY25.

Valiant Laboratories Financial Highlights


For the full year FY2025–2026, revenue reached ₹138.82 crore and profit touched at ₹-2.2 crore.

Valiant Laboratories Share Price Today


As of 18 Jan 2026, Valiant Laboratories share price is ₹64.7. The stock opened at ₹67.3 and had closed at ₹65 the previous day. During today’s trading session, Valiant Laboratories share price moved between ₹63.75 and ₹67.30, with an average price for the day of ₹65.53. Over the last 52 weeks, the stock has recorded a low of ₹63.50 and a high of ₹115.54. In terms of performance, Valiant Laboratories share price has declined by 40.2% over the past six months and has declined by 38.1% over the last year.
Read More
View details of Market Depth

Valiant Laboratories Fundamental

Market Cap (in crs)

351.46

Face Value

10

Turnover (in lacs)

12.60

Key Metrics

Qtr Change %
New 52W Low in past week
-21.8
Dividend yield 1yr %
0

Valiant Laboratories Key Financials

View more
Loading chart...
Valiant Laboratories Quarterly Revenue
Valiant Laboratories Yearly Revenue
Valiant Laboratories Quarterly Net Profit/Loss
Valiant Laboratories Yearly Net Profit/Loss

Valiant Laboratories Result Highlights

  • Valiant Laboratories Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 89.5%.

  • Its expenses for the quarter were up by 3.9% QoQ and 62.7% YoY.

  • The net profit decreased 89.0% QoQ and decreased 104.2% YoY.

  • The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.04 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Valiant Laboratories Shareholding Pattern

Promoter
74.9%
Public
25%

Valiant Laboratories Technical Analysis

Moving Averages Analysis
64.71
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Day EMA5
65.70
Day EMA10
67.10
Day EMA12
67.50
Day EMA20
68.40
Day EMA26
69.00
Day EMA50
71.80
Day EMA100
77.10
Day EMA200
85.10
Delivery & Volume
Loading chart...

Day

70.10%

Week

71.30%

Month

38.50%

Delivery & Volume

65.25
Pivot
Resistance
First Resistance
66.76
Second Resistance
68.80
Third Resistance
70.31
Support
First Support
63.21
Second support
61.70
Third Support
59.66
Relative Strength Index
38.60
Money Flow Index
41.57
MACD
-1.53
MACD Signal
-0.96
Average True Range
4.57
Average Directional Index
26.78
Rate of Change (21)
-0.80
Rate of Change (125)
-42.14
Compare

Valiant Laboratories Latest News

15 JAN 2026 | Thursday
07 JAN 2026 | Wednesday
26 DEC 2025 | Friday

Please be aware that Valiant Laboratories stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account